Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Merck & Co Inc on Tuesday said its Lynparza drug, developed alongside AstraZeneca PLC, improved survival rates for some sufferers of prostate cancer.
Results from a phase three probe showed Lynparza, in tandem with abiraterone plus prednisone ‘significantly’ improved progression-free survival, compared to users of just abiraterone plus prednisone.
The latter treatment is the standard of care for sufferers of metastatic castration-resistant prostate cancer. Metastatic cancer is a form of the disease which spreads to distant parts of the body. Castration-resistant prostate cancer is a form of the disease which continues to spread even when the level of testosterone in the body is reduced.
Merck & Co shares ended 4.1% higher at $88.03 each in New York on Tuesday. Astra shares rose 0.8% to 10,130.00p.
Copyright 2022 Alliance News Limited. All Rights Reserved.